Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron stands to net an initial US$5mln as US company runs rule over its retinal stem cell technology

It has inked a three-month exclusivity deal with an unnamed American speciality pharma group
eye
The company is ready to partner up to develop its ground-breaking hRPC retinal stem cell technology and therapeutic programmes
ReNeuron Group PLC (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking retinal stem cell technology and therapeutic programmes.
 
It has signed an exclusivity agreement with an unnamed US-based speciality pharmaceutical company, which it hopes will lead to a definitive accord later this year.

WATCH: ReNeuron CFO on the​ exclusivity agreement

The financial nuts and bolts are as follows: ReNeuron will receive a non-refundable US$2.5mln payment for granting a three-month period of exclusivity and will get the same again following the completion of "certain due diligence activities" during that time.
 
The definitive pact is expected to grant the American firm worldwide licensing rights to the ReNeuron advance, though the deal would exclude China.
 
In return, the UK group, which is also working on a cell-based therapy for stroke victims, would receive success-based milestone payments on top of what has already been pledged.

Active discussions taking place on other programmes

ReNeuron said its putative partner has the financial capacity as well as the clinical and commercial nous to "accelerate and maximise the value of the company's hRPC technology".
 
Chief executive Olav Hellebø said the group had been "actively engaged in discussions with various parties" before signing the three-month exclusivity.
 
And he added that ReNeuron was in detailed discussions with a number of companies in connection with its other programmes.
 
"It is highly encouraging that our technologies and therapeutic programmes are attracting increasing interest from commercial third parties, reflecting the positive progress these programmes are making through pre-clinical and clinical development and their potential to address major unmet medical needs," he went on.

Two platforms 

The company has two distinct platforms. Its CTX cell lines are being developed for serious conditions such as stroke, while its human retinal progenitor cells (hRPC) have been deployed in Phase I/IIa trials for people with a blindness-causing condition called retinitis pigmentosa. 

The shares jumped 22% on the back of Wednesday’s announcement, pushing the stock to just shy of £1. 

 

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use